Figure 1.

Countries and study sites participating in I-MOVE-COVID-19 and VEBIS hospital vaccine effectiveness studies, by provision of data for this analysis, Europe, 2021–2022

I-MOVE: Influenza – Monitoring Vaccine Effectiveness in Europe; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; VEBIS: Vaccine Effectiveness, Burden and Impact Studies.

Sixteen participating sites: Belgium (BE), Croatia (HR), Czechia (CZ), France (FR), Germany (DE), Greece (GR), Hungary (HU), Ireland (IE), Lithuania (LT), Luxembourg (LU), Malta (MT), the Netherlands (NL), Portugal (PT), Romania (RO), Spain 11 regions (ES), Spain Navarra region (NA). Eleven included in this analysis: BE, ES, FR, HR, IE, LT, MT, NA, NL, PT, RO.